Step 1 · Screen
Nonfasting lipid panel
Figure 3 routes nonfasting non–HDL-C ≥145 mg/dL or TG ≥200 mg/dL to a fasting lipid panel. The narrative also says a fasting panel can be considered when HDL-C is <40 mg/dL.
Pediatric lipid decision support
Pediatric Hypertriglyceridemia
An original visual guideline, deterministic calculator, and next-steps tool derived from the 2026 American Heart Association scientific statement. The statement—not an LLM—is the runtime source of clinical logic.
Fasting triglyceride severity map
Table 1 defines the five bands. The therapeutic emphasis transitions from ASCVD prevention to pancreatitis prevention as chylomicrons become prominent.
Clinical workflow
A simplified original rendering of the statement's Figure 3 workflow, with Table 1 governing severity cut points.
Step 2 · Classify
Use fasting TG for treatment decisions
Apply the five Table 1 ranges: acceptable, mildly elevated, moderately elevated, severely elevated, and very severely elevated.
Step 3 · Act
Match risk, workup, diet, and follow-up
Evaluate secondary causes for hypertriglyceridemia, use range-specific lifestyle targets, and escalate to lipid-specialist/genetic/pancreatitis branches as severity rises.
Calculator + next steps
Enter only the information needed to select the statement's pathway. This tool does not store or transmit patient data.
Enter lipid data
The result will show the applicable AHA 2026 pathway, source-derived next steps, follow-up branch, and conditional decisions.
Secondary causes checklist
Directly organized from Table 3. The statement advises evaluating secondary causes and other ASCVD risk factors even when a genetic cause is suggested.
Primary source + implementation boundary
The tool is intentionally source-locked. Other guidelines are not used to overwrite this statement's decision logic.
Canonical source
- Table 1: fasting TG severity categories, predominant lipoprotein, lifestyle targets, pharmacotherapy considerations, and primary goal.
- Figure 3: screening trigger, fasting-panel workflow, laboratory/referral branches, and follow-up intervals.
- Table 3: secondary causes.
- Narrative: clarification and expansion of abbreviated management language.
Explicit implementation choices
This is an original clinical decision aid. It does not reproduce or modify the AHA's published figure artwork. It translates source-supported clinical rules into a deterministic interface and records known internal source discrepancies rather than silently reconciling them.